Globally, more than 59 million cases of coronavirus were reported until Tuesday morning, according to data compiled by Johns Hopkins University (JHU).
Meanwhile, the death toll from coronavirus climbed to 1,395,658.
The United States has recorded the most cases since the start of the pandemic with 12,414,292 followed by India with 9,139,865 and Brazil with 6,087, 608.
Around 83,000 people in the US are hospitalised with Covid-19, according to the Covid Tracking Project. Infections have led to a shortage of hospital beds and health care workers, and they threaten non-Covid-19-related surgeries and other care, reports AP.
Brazil has the world's second-highest Covid-19 death toll, after the United States, and the third-largest outbreak, after the US and India.
Brazil on Monday reported 302 new deaths from Covid-19, raising the death toll to 169,485.
In its daily pandemic report, the Ministry of Health said tests detected 16,207 new cases of infection. The country's first case was confirmed on February 26.
Meanwhile, India reported 37,975 new cases in 24 hours, according to the Health Ministry's update as of Tuesday morning.
More than 133,738 deaths were also reported from the country.
Covid-19 situation in Bangladesh
Bangladesh reported 2,419 new coronavirus cases in 24 hours until Monday, pushing up the tally to 449,760.
Besides, the country recorded 28 more Covid-19 deaths during the period, taking fatalities to 6,416. In the last seven days, 201 people lost their lives to Covid-19 in the country.
The death rate stood at 1.43 percent, the Directorate General of Health Services said.
So far, 364,611 patients – 81.07 percent -- including 2,183 in the last 24 hours, have recovered.
Bangladesh reported its first cases on March 8. The infection number reached the 300,000-mark on August 26. The first death was reported on March 18 and the death toll exceeded 6,000 on November 4.
Covid-19 vaccine raises hope
Pharmaceutical company AstraZeneca on Monday said that late-stage trials showed its coronavirus vaccine was up to 90 percent effective, giving public health officials hope they may soon have access to a vaccine that is cheaper and easier to distribute.
The results are based on interim analysis of trials in the UK and Brazil of a vaccine developed by Oxford University and manufactured by AstraZeneca. No hospitalisations or severe cases of Covid-19 were reported in those receiving the vaccine.